Hyderabad|India|September'2009:
Bharat Biotech
International (BBIL), a leading manufacturer of vaccines and
biotherapeutics announced its Anti-Staphylococcal Molecule ‘Lysostaphin’
has secured patent rights in US,
Europe, China, Australia including other nations.
Lysostaphin is a potent anti-Staphylococcal therapeutic with a
targeted specificity against
Staphylococcus aureus
(S.aureus).
It is a glycylglycine endopeptidase that rapidly cleaves the
peptidoglycan backbone of S.aureus, lysing the cell in all its metabolic
states.
S. aureus
causes a broad spectrum of diseases, including superficial lesions,
such as wound
infections; systemic and life-threatening conditions, such as
endocarditis,
osteomyelitis,
pneumonia, brain
abscesses,
meningitis, and bacteremia; and toxinoses, such as
food poisoning, scalded skin syndrome, and
toxic shock syndrome.
Making the
announcement Dr. Krishna Ella, Chairman and Managing Director of
Bharat Biotech said patent rights for Lysostaphin is a significant
milestone in our new therapeutic product development program and
paves way to develop products for regulated markets, in addition to
India .
A pre-IND (Investigational
New Drug ( IND ) Application meeting) of the pre-clinical
data has already been held with USFDA.
Lysostaphin
being bactericidal in action is indifferent to
antibiotic resistance and could be drug of choice for
treating life threatening S.aureus bacteremia caused drug resistant
S.aureus.
Bharat Biotech
is a multidimensional
biotechnology company specialising in product-oriented
research, development and manufacturing of vaccines and
biotherapeutics and it has been in the forefront of developing and
manufacturing world class vaccines and it is currently developing
Swine Flu vaccine to combat H1N1 virus epidemic in India and
other countries.
BBIL undertakes
projects of immense social and scientific relevance in the field of
-
Molecular Biology
-
Microbiology
-
Virology
-
Immunology
-
Biochemistry
-
Clinical
Research
-
Industrial
Biotechnology
Bharat Biotech
International has
13
Patents Filed in ( India ),
12
Patents Filed (International) and it has been granted
8
Patents ( India )
5
Patents (International).
BBIL targets
Lysostaphin for regulated markets